Acquired Immunodeficiency Syndrome Market - Forecast(2024 - 2030)

Acquired Immunodeficiency Syndrome Market Overview              

The Acquired Immunodeficiency Syndrome market size is estimated to reach $38.9 billion by 2026, growing at a CAGR of 3.9% during the forecast period 2021-2026. Acquired Immunodeficiency Syndrome (AIDS) is a range of conditions caused by the Human Immunodeficiency Virus (HIV) infection. The virus primarily attacks and weakens the host's immune system, making them highly susceptible to secondary infections such as Tuberculosis and human cytomegalovirus (HCMV) as well as tumors and Kaposi sarcoma. HIV is transmitted through unprotected sex, blood transfusions, used hypodermic needles, and from mother to child during pregnancy, delivery, or breastfeeding. Although there is no cure for AIDS, treatment largely involves antiretroviral therapy, while others include preventive treatment and treatment of opportunistic infections. A large global population with AIDS is anticipated to drive the market during the forecast period. However, lack of awareness among the infected people and limited access to high-quality treatment is projected to hamper growth.

Report Coverage

The report: “Acquired Immunodeficiency Syndrome Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Acquired Immunodeficiency Syndrome Market.
By Drug Types: Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTI), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI), Fusion Inhibitors, Attachment inhibitors, CCR5 antagonists and post-attachment inhibitors, Protease Inhibitors, Integrase Inhibitors, and PrEP & PEP.
By Distribution Channel: Hospital pharmacies, retail pharmacies, online pharmacies, and others.
By Geography: North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, and Rest of South America) and Rest of World (the Middle East and Africa).

Key Takeaways

• Geographically, the North American Acquired Immunodeficiency Syndrome market accounted for the largest share in 2020 owing to high patient awareness and the presence of well-developed healthcare infrastructure.

• An increase in the cases of HIV infection in developing and underdeveloped regions is projected to increase demand for antiretroviral drugs. However, high side-effects associated with the medication are anticipated to challenge demand generation.

• Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Acquired Immunodeficiency Syndrome Market Report.

Acquired Immunodeficiency Syndrome Market Segment Analysis-By Drug Type

Based on Drug Type, the Acquired Immunodeficiency Syndrome Market is segmented into Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTI), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI), Fusion Inhibitors, Attachment inhibitors, CCR5 antagonists and post-attachment inhibitors, Protease Inhibitors, Integrase Inhibitors, PrEP & PEP. The NRTI segment is anticipated to have the largest share of the market in 2020 and is poised to dominate the market during the forecast period 2021-2026. This is attributed to the fact that these drugs effectively block the enzymes necessary for new virus production by inserting themselves into the viral DNA. NRTIs were the first class of HIV drugs and forms a major component of the Highly Active Antiretroviral Therapy (HAART) treatment. The PrEP and PEP segment is anticipated to grow the fastest at a CAGR of 4.3% owing to their property to reduce the risk of getting HIV and even prevent HIV infection if administered within 72 hours of transmission.

Acquired Immunodeficiency Syndrome Market Segment Analysis-By Distribution Channel

The Acquired Immunodeficiency Syndrome Market based on Distribution Channel can be further segmented into Hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacies segment accounted for the largest share of the market in 2020. This is owing to the fact that drugs for HIV treatment are highly regulated in many countries and therefore, only select authorized pharmacies are allowed to sell these drugs. Hospital pharmacies are usually given this license more than the other channels of distribution.  The online pharmacy segment is projected to witness the fastest growth during the forecast period with a CAGR of 4.5% in the forecast period, especially in the developed regions owing to the covid-19 pandemic and resulting restrictions. Since patients with AIDS have a weakened immune system, exposure to the Covid-19 virus can have severe health effects. Online delivery of essential drugs ensures patient’s safety as well as convenience.

Acquired Immunodeficiency Syndrome Market Analysis-By Geography

The Acquired Immunodeficiency Syndrome Market based on Geography can be segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. The North American segment is projected to dominate the acquired immunodeficiency syndrome market during the forecast period 2021-2026 with a market share of 34% owing to the presence of highly developed healthcare infrastructure, low shortage of essential drugs, high patient awareness levels, and a relatively large target patient population. For instance, there are 1.2 million people who have AIDS in the US alone. The Rest of the Word segment is anticipated to register the fastest growth during the forecast period owing to the high prevalence and increasing awareness of HIV infection in Africa. According to the World Health Organization (WHO), around 67% of the people living with HIV are in Africa.

Acquired Immunodeficiency Syndrome Market Drivers

Increase in Research and Development is Projected to Drive Market Growth

The rapid rise in both public and private investment into the development of more effective drugs for the treatment and prevention of AIDS is anticipated to drive the market. As these drugs become more effective, it significantly increases the patient’s quality of life and lifespan. AIDS-related deaths declined by 61% in 2020 compared to 2004. 690,000 AIDS-related deaths were reported worldwide in 2020 compared to 1.2 million in 2010. 73% of the population with HIV are undergoing Antiretroviral treatment, and 66% of them have become virally suppressed to undetectable levels. Moreover, innovative drugs such as PEP can even prevent HIV infection if consumed within 72 hours of exposure to the virus.

Rapid Increase in Development and Disposable Income is Anticipated to Boost Product Demand

The rapid growth in the economic development of several countries in the Asia Pacific is anticipated to drive the demand as an increase in disposable income, and public healthcare spending will enable higher accessibility and affordability to long-term HIV treatment options. More than 5.7 million or 15% of the population with AIDS were from the Asia Pacific. Moreover, around 300,000 new infections were recorded in the region in 2020. The increase in GDP has enabled countries such as India, China, and Bangladesh to increase investment in the prevention and treatment of HIV. For instance, the GDP growth of India, Bangladesh, and China was estimated to be 10.0%, 6.0%, and 7.7%, respectively, in 2021.

Acquired Immunodeficiency Syndrome Market Challenges
The Risk of Side-Effects of Antiretroviral Treatment is Anticipated to Hamper Market Growth

The high risk of side-effects of antiretroviral treatments is a major factor that may discourage long-term usage of such medication, resulting in a reduction of demand. Side-effects from antiretroviral agents include lipodystrophy syndrome, dyslipidemia, diabetes mellitus, diarrhea, and an increased risk of cardiovascular disease. lipodystrophy syndrome causes the rapid loss of subcutaneous fat while Dyslipidemia is the increase in presence of lipids in the blood. Moreover, they may also lead to birth defects and therefore not given to women hoping to have children.

Covid-19 Pandemic and Subsequent Restrictions is Projected to Limit Growth Opportunities

The rapid spread of the Covid-19 virus and the increased cases of hospitalizations have led to the straining of the global healthcare system. Moreover, the economic impact of the pandemic has also caused a reduction of other essential services such as the distribution of HIV medication in low and middle-income countries. It was reported that the disruption of HIV services was around 75% in some countries in Africa and Asia. Visits of HIV patients to Hospitals during the pandemic have also reduced owing to their suppressed immune systems.

Acquired Immunodeficiency Syndrome Market Industry Outlook:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Acquired Immunodeficiency Syndrome Market. The top 10 companies in of the industry include:

• GlaxoSmithKline plc.
• Abbott
• AstraZeneca
• Pfizer Inc.
• Sanofi
• Gilead Sciences, Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• Shire Plc
• Merck KGaA

Partnerships/Product Launches:

• In March 2021, Gilead Sciences and Merck announced that they have entered into an agreement to co-develop and co-commercialize long-acting treatments in HIV.
• In January 2021, The US Food and Drug Administration (FDA) approved a long-acting HIV injection from GlaxoSmithKline’s HIV treatment division, ViiV Healthcare. The drug is to be administered once a month and acts as an alternative to daily pills.

Relevant Links:

HIV Diagnosis Market – Forecast (2021 - 2026)
Report Code: HCR 64783

Antiviral Drug Market – Forecast (2021 - 2026)
Report Code: HCR 1363

For more Lifesciences and Healthcare related reports, please click here